Navigation Links
Jennerex Reports Positive Mechanistic Proof-of-Concept Clinical Trial Results Using JX-594 to Treat Metastatic Melanoma
Date:8/2/2011

SAN FRANCISCO, Aug. 2, 2011 /PRNewswire/ -- Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic products for cancer, today announced that positive results from a proof-of-concept clinical trial using JX-594 to treat patients with metastatic melanoma were published in the peer-reviewed journal Molecular Therapy.

"This clinical trial in metastatic melanoma provides additional key information for our JX-594 program and complements the ongoing clinical development of JX-594, which is expected to enter a randomized Phase 2b trial in advanced liver cancer later this year," said David Kirn, M.D., president and chief executive officer of Jennerex. "Specifically, JX-594 replication was observed following multiple rounds of intratumoral JX-594 therapy, providing proof-of-concept data for the potential benefit of chronic administration regimens of the product."

The mechanistic proof-of-concept study enrolled 10 treatment-refractory Stage IV melanoma patients, eight of whom completed the study. All patients received up to nine weekly intratumoral injections of JX-594 at a low dose (less than 10 percent of the dose given in other JX-594 trials). Evidence of JX-594 activity was assessed in blood samples and tumor biopsies. Blood samples collected over the course of treatment demonstrated JX-594 replication after repeated dosing as well as the expression and functionality of JX-594 encoded transgenes. Tumor biopsies showed tumor cell necrosis (death) and immune cell recruitment into tumors. JX-594 was safe and well-tolerated, with flu-like symptoms as the most common side effect for patients.

JX-594: A Multi-Mechanistic Approach To Targeting Cancer

JX-594 is a proprietary, engineered oncolytic virus that is designed to selectively target and destroy cancer cells. JX-594 is designed to attack cancer through three diverse mechanisms of act
'/>"/>

SOURCE Jennerex, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Jennerex and Partners Present Positive JX-594 Randomized Phase 2 Clinical Data Showing Promising Survival Benefit in Patients with Advanced Liver Cancer
2. Jennerex to Present JX-594 Liver Cancer Clinical Data at American Society of Gene and Cell Therapy Meeting
3. Jennerex Appoints James M. Burke, M.D. Vice President, Clinical Research
4. Jennerex and Transgene Enter Into an Exclusive Partnership for the Development and Commercialization of JX-594 for the Treatment of Cancers
5. Jennerex Completes Fully Subscribed Private Placement for Aggregate Gross Proceeds of $8.6 Million
6. Jennerex Reports Positive Phase 1 Results for JX-594 Administered Intravenously
7. Jennerex Adds Industry Veteran Paul Cleveland to Board of Directors
8. Jennerex Completes Over-Subscribed Series C Financing for Aggregate Gross Proceeds of Over $5.5 Million
9. Jennerex Closes $5 Million First Tranche of Series C Financing
10. Nature Reviews Publishes Article About Jennerexs Multi-Mechanistic Cancer Therapeutic
11. Jennerex Appoints Samantha Miller as Vice President of Corporate Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2015)... Santa Clara CA (PRWEB) May 06, 2015 ... microscopy (AFM) today announced NX-Hivac, the only high vacuum ... and future needs for failure analysis semiconductor manufacturing. Park ... are interested in failure analysis solutions in highly doped ... are now required. , The high vacuum scanning ...
(Date:5/6/2015)... 2015 Histogen, Inc., a regenerative ... of cells grown under simulated embryonic conditions, will ... candidate for melanoma during the 2015 Society of ... 6-9, 2015 in Atlanta, GA. , Histogen has ... soluble material with anti-oncologic properties, with potential benefit ...
(Date:5/6/2015)... 2015 The Remedy Group , ... for the specialty pharmacy industry, will be exhibiting, presenting, ... Specialty Pharmacy Summit. The Summit will be held May ... and is the largest annual gathering for the specialty ... from pharmacy providers, pharma/biotech manufacturers, and payers, to learn ...
(Date:5/5/2015)... , May 5, 2015  Blueprint Medicines ... of its initial public offering of 9,367,708 shares ... of $18.00 per share, including shares of common ... underwriters of their option to purchase additional shares. ... to Blueprint Medicines were approximately $168.6 million, before underwriting ...
Breaking Biology Technology:Park Systems Introduces Park NX-Hivac, a High Vacuum SSRM AFM System for Optimal Results in Semiconductor Manufacturing Failure Analysis 2Park Systems Introduces Park NX-Hivac, a High Vacuum SSRM AFM System for Optimal Results in Semiconductor Manufacturing Failure Analysis 3Novel Immunomodulatory Treatment Induces Apoptosis in Melanoma 2The Remedy Group presenting at the 2015 Armada Specialty Pharmacy Summit: The Pitfalls to Growth and Maintaining the Patient Experience 2Blueprint Medicines Announces Closing of Initial Public Offering 2
... its worldwide leadership in the search for new ... received two of 12 prestigious grants for cutting-edge ... Semiconductor Research Corporation,s Nanoelectronics Research Initiative (SRC-NRI) and ... allowed to submit two proposals each to the ...
... BRANFORD, Connecticut and TEMPE, Arizona, October 11, 2011 ... ) and Arizona Technology Enterprises (AzTE) announced today an ... Lindsay at the Biodesign Institute at Arizona State University ... Center for the development of a revolutionary DNA sequencing ...
... and QbD remains a field that still lacks clarity and commonality ... the PAT and QbD community it was  found that 53% of ... was due to a lack of personnel with expertise in the ... to industry specialists from the PAT and QbD community and creates ...
Cached Biology Technology:Notre Dame researchers awarded millions to develop radically new computers 2Roche Licenses Nanopore Sequencing Technologies from Arizona State University and Columbia University for Rapid, Affordable DNA Sequencing 2Roche Licenses Nanopore Sequencing Technologies from Arizona State University and Columbia University for Rapid, Affordable DNA Sequencing 3Roche Licenses Nanopore Sequencing Technologies from Arizona State University and Columbia University for Rapid, Affordable DNA Sequencing 4Establishing the Correct QbD Strategies and Tools Early in the Development Process is Key to Ensuring we Have Robust Quality Products Downstream 2
(Date:4/14/2015)... April 14, 2015 NXT-ID, Inc. (NASDAQ: ... company focused on the growing mobile commerce market, announces ... the 2015 New York Design Awards under the category  ... York City Design Awards are part of a global ... 2,500 ratings from the marketplace, industry and judging panel. ...
(Date:4/10/2015)... , April 10, 2015 Research ... of the "Security Competitive Profiles - NEC" ... , NEC will continue to supply a ... the market, with a company focus on the development ... Winning opportunities in the Asia-Pacific ...
(Date:4/6/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... on the growing mobile commerce market, announced today ... MINIATURE, MULTI-PURPOSE ANTENNA METHOD AND SYSTEM FOR ... introduces a new revolutionary method and system to ... of miniature antenna modules for multiple purposes including ...
Breaking Biology News(10 mins):NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3NEC Security Competitive Profile 2015 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 3NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 4
... diversity of ladybird beetle species is linked to their ... of ,herds, of tiny, soft-bodied scale insects from under ... the evolutionary history of ladybird beetles (family Coccinellidae ... evolutionary shift was from feeding on hard-bodied ("armoured") scale ...
... productivity and health of horticultural crops depends on the ability ... is a function of the amount of leaf area, the ... light energy. One estimate of a crop,s ability to capture ... 1947, the concept of the LAI was defined as the ...
... MIAMI Shark populations over the last 50 years ... finning, human activities have affected their populations and made ... article in Current Issues in Tourism by ... R.J. Dunlap Marine Conservation Program at the University of ...
Cached Biology News:Ladybirds -- wolves in sheep's clothing 2New non-destructive method to estimate leaf area index in vegetables 2Conservation dollars and sense 2
... Continuous flow of media and other ... little lab space, The speed of each ... and flow set points, are exactly maintained. ... equipped with variable tube types, which allows ...
... culture flask is designed for culturing organisms requiring a ... a heavy beaded rim to protect against chipping and ... 38mm and takes a No. 6.5 rubber stopper. • ... source smaller than the base of the flask. Uneven ...
... cassette is designed to allow ampicillin selection ... gb2 driving the gene for ampicillin resistance ... Em7 promoter. It mediates higher transcription efficiency ... synthetic polyadenylation signal terminates the ampicillin expression. ...
... FRT-amp-FRT cassette is designed to ... The prokaryotic promoter gb2 driving the gene ... version of the Em7 promoter. It mediates ... Tn5 promoter. A synthetic polyadenylation signal terminates ...
Biology Products: